Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan


  • Shawn E. ChristEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_1586


Følling’s disease; Hyperphenylalaninemia; Imbecillitas phenylpyrouvica; Oligophrenia phenylpyruvia; PKU


Phenylketonuria (PKU) is a rare autosomal recessive condition characterized by an inability to metabolize the amino acid phenylalanine. The most common variation of PKU is associated with a mutation of the phenylalanine hydroxylase (PAH) gene, located on chromosome 12q. Individuals with PKU have an absence of or significant deficiency in the PAH enzyme. Functional PAH is necessary for the metabolism of phenylalanine into tyrosine, a precursor for the neurotransmitter dopamine. Disruption of this metabolic process results in higher-than-normal levels of phenylalanine as well as decreased tyrosine levels. The excessive phenylalanine further competes with the available tyrosine and other large neutral amino acids (LNAAs) to cross the blood-brain barrier, ultimately resulting in decreased synthesis of dopamine and other neurotransmitters within the brain.


This is a preview of subscription content, log in to check access.

References and Readings

  1. Blau, N. (Ed.). (2006). PKU and BH4: Advances in phenylketonuria and tetrahydrobiopterin. Heilbronn: SPS.Google Scholar
  2. Christ, S. E. (2003). Asbjørn Følling and the discovery of phenylketonuria. Journal of the History of the Neurosciences, 12, 44–54.CrossRefPubMedPubMedCentralGoogle Scholar
  3. National Institutes of Health Consensus Development Panel. (2001). National Institutes of Health consensus development conference statement: Phenylketonuria: Screening and management, October 16-18, 2000. Pediatrics, 108, 972–982.CrossRefGoogle Scholar
  4. Welsh, M. C., Pennington, B. F., Ozonoff, S., Rouse, B., & McCabe, E. R. R. (1990). Neuropsychology of early-treated phenylketonuria: Specific executive function deficits. Child Development, 61, 1697–1713.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Al Hafid, N., & Christodoulou, J. (2015). Phenylketonuria: A review of current and future directions. Translational Pediatrics, 4(4), 304–317.PubMedCentralPubMedGoogle Scholar
  6. Camo, K., Parisi, M., Acosta, P., Berry, G., Bilder, D., Blau, N., et al. (2014). Phenylketonuria scientific review conference: State of the science and future research needs. Molecular Genetics and Metabolism, 112(2), 87–122.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of MissouriColumbiaUSA